SINGAPORE, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- Biosensors
International Group, Ltd. (Bloomberg: BIG SP), today announced that on
September 6, 2005 it was granted a patent from the United States Patent and
Trademark Office covering the technology behind its drug-eluting stents
(''DES''). Specifically, this U.S. patent, (Patent Number 6939376) covers the
use of anti-restenotic, immuno-suppressive drugs including Everolimus, in
combination with a biodegradable drug-release polymer coating on an
endovascular stent. The patent was filed in April 2002, and is valid in the
U.S. for 20 years from the filing date. The Company has also filed for the
same patent in Australia, Japan and Europe, which it is anticipating to
''Intellectual assets are particularly important in a fast growing and
competitive segment such as the multi-billion dollar DES market,'' said
Yoh-Chie Lu, Chairman and CEO of Biosensors. "We have a strong belief that
bioresorbable polymers will be a key factor for the long term success of DES.
The positive STEALTH clinical trial results is consistent with this and we
believe that the combination therapy, as covered by this patent, will be a
step forward in treating coronary artery diseases. Securing a patent that
covers a core technology in this area will bring us one step closer to
achieving our vision of becoming a leader in DES,'' he said.
The DES technology covered by this patent has clinically been shown to
reduce restenosis in humans when compared to bare metal stents as demonstrated
in the FUTURE I and II, and STEALTH clinical trials conducted by Biosensors.
Restenosis is the renarrowing of the coronary arteries following stent
implantation. The stent, which is a tiny, expandable mesh-like tube, acts as
a scaffold inside the coronary artery and helps keep the artery open after
balloon angioplasty. The patent also covers the technology used in the
Company's flagship DES, BioMatrix(TM), which uses Biosensors' proprietary
Biolimus A9(TM) drug, bioresorbable polymer, S-Stent(TM) and stent delivery
catheter, all of which have been developed in-house. Biosensors also has
other patents pending on the Biolimus A9TM drug technology.
Biosensors believes that this new patent will go a long way in
strengthening its intellectual property portfolio. The Company will continue
to secure, leverage and when necessary, vigorously defend its intellectual
property as it develops more inventions in the medical specialties it
About Biosensors International Group, Ltd.
Biosensors develops, manufactures and markets innovative medical devices
used in interventional cardiology and critical care procedures. Biosensors is
well-positioned to emerge as a leader in drug-eluting stents, an evolving
therapy that is rapidly gaining market share from traditional therapies such
as bare-metal stenting and open-heart surgery. Biosensors has internally
developed technology to address each component of a drug-eluting stent system,
including a stent, a stent delivery catheter, a bioresorbable polymer and a
proprietary anti-restenotic drug. It is pursuing two separate drug-eluting
stent programs, BioMatrix(TM) and Axxion(TM), and has licensed aspects of its
drug-eluting stent technology to four companies.
Forward Looking Statements
Certain statements herein include forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally can be identified by the use of
forward-looking terminology, such as "may," "will," "expect," "intend,"
''estimate,'' ''anticipate,'' ''believe,'' ''project'' or ''continue'' or the
negative thereof or other similar words. All forward-looking statements
involve risks and uncertainties, including, but not limited to, customer
acceptance and market share gains, competition from companies that have
greater financial resources; introduction of new products into the marketplace
by competitors; successful product development; dependence on significant
customers; the ability to recruit and retain quality employees as Biosensors
grows; and economic and political conditions globally. Actual results may
differ materially from those discussed in, or implied by, the forward-looking
statements. The forward-looking statements speak only as of the date of this
release and Biosensors assumes no duty to update them to reflect new, changing
or unanticipated events or circumstances.
Media Contact Information:
Biosensors International Group
Ms Tina Lim, Executive, Corporate Communications
For investor related enquiries, please write to email@example.com.
WeR1 Consultants Pte Ltd
SOURCE Biosensors International Group, Ltd.